Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT05653752
Other study ID # YL202-INT-101-01
Secondary ID
Status Active, not recruiting
Phase Phase 1
First received
Last updated
Start date December 20, 2022
Est. completion date December 2025

Study information

Verified date July 2023
Source MediLink Therapeutics (Suzhou) Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, multicenter, open-label, first-in-human study of YL202 conducted in the United States and China. The study will evaluate the safety and tolerability of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated NSCLC or hormone receptor (HR)-positive and HER2-negative BC, which have been heavily treated by standard treatment.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 80
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Informed of the trial before the start of the trial and voluntarily sign their name and date on the informed consent form - Aged =18 years - Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 2 - Adequate organ and bone marrow function - Female patients of childbearing potential must agree to use a highly effective form of contraception and not donate, or retrieve for their own use, ova from the time of screening and throughout the study period, and for at least 6 months after the last dose of study drug. Male patients must agree to use a highly effective form of contraception and not freeze or donate sperm from the time of screening and throughout the study period, and for at least 6 months after the last dose of study drug. - Life expectancy of =3 months - Able and willing to comply with protocol visits and procedures - For NSCLC patients: - Have a histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC not amenable to curative surgery or radiation - Have a documentation of an EGFR-activating mutation (exon 19 deletion or L858R) detected at diagnosis or thereafter - Have documentation of disease progression on or after, or are intolerant to prior standard treatment regimens for locally advanced or metastatic disease. - For BC patients: - Have a histologically or cytologically confirmed diagnosis of unresectable locally advanced or metastatic HR-positive and HER2-negative BC (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines) - Have documentation of disease progression on or after, or are intolerant to prior standard treatment regimens for locally advanced or metastatic disease. - Have at least 1 measurable tumor lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 Exclusion Criteria: - Intolerant to prior treatment with a topoisomerase I inhibitor or an ADC that consists of a topoisomerase I inhibitor, including but not limited to topotecan, irinotecan, and DXd (e.g., severe diarrhea) - Concurrent enrollment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study - Inadequate washout period for prior anticancer treatment before the first dose of study drug - Undergone major surgery (not including diagnostic surgery) within 4 weeks before the first dose of study drug or expect major surgery during the study - Prior allogeneic bone marrow transplantation or solid-organ transplantation - Received systemic steroids (>10 mg/day of prednisone or its equivalent) or other immunosuppressive therapy within 2 weeks before the first dose of study drug. The following are exceptions to this criterion: - Intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) - Systemic steroids at physiological doses as replacement therapy (e.g., physiological corticosteroid replacement therapy for adrenal or pituitary insufficiency) - Steroids as premedication for hypersensitivity reactions (e.g., computed tomography [CT] scan premedication) - Received any live vaccine within 4 weeks before the first dose of study drug or intend to receive a live vaccine during the study - A history of leptomeningeal carcinomatosis - Brain metastases or spinal cord compression unless asymptomatic or treated and stable off steroids and anti-convulsants for at least 2 weeks before the first dose of study drug - Uncontrolled or clinically significant cardiovascular disease. - A history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that requires steroids, current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening - Clinically significant concomitant pulmonary disease. - Clinically significant corneal disease - Have a diagnosis of Gilbert's syndrome - Uncontrolled third-space fluid (e.g., pleural effusions, ascites, pericardial effusions) that requires repeated drainage - Active gastric and duodenal ulcers, ulcerative colitis, or other gastrointestinal conditions that may cause bleeding or perforation by the investigator's discretion - Active infection that requires systemic therapy within 1 week before the first dose. Patients receiving prophylactic anti-infective therapy (e.g., to prevent a urinary tract infection or chronic obstructive pulmonary disease exacerbation) may be eligible after discussion with the sponsor. - Known human immunodeficiency virus (HIV), hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Patients with HIV, HBV, or HCV infection may be enrolled after evaluation of eligibility based on FDA's guideline Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections - Any other primary malignancy within 3 years before the first dose of study drug, except adequately resected non-melanoma skin cancer, curatively treated in situ disease, or other curatively treated solid tumors - Unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia and pigmentation) not yet resolved to NCI CTCAE Grade =1, baseline, or the level specified in the inclusion/exclusion criteria. Patients with chronic Grade 2 toxicities who are asymptomatic or adequately managed with stable medication may be eligible after discussion with the sponsor. - A history of severe hypersensitivity reactions to the drug substances, inactive ingredients in the drug product, or other monoclonal antibodies - Women who are breastfeeding or pregnant as confirmed by pregnancy tests performed within 3 days before the first dose - Any illness, medical condition, organ system dysfunction, or social situation, including but not limited to mental illness or substance/alcohol abuse, deemed by the investigator to be likely to interfere with a patient's ability to sign informed consent, adversely affect the patient's ability to cooperate and participate in the study, or compromise the interpretation of study results.

Study Design


Intervention

Drug:
YL202
YL202 is provided as the lyophilized powder, 200 mg/vial. YL202 will be given intravenously once every 3 weeks (Q3W) as a cycle. The initial dose of YL202 will be infused IV into each patient for 90 ±10 minutes. If there is no infusion-related reaction after the initial dose, the second and subsequent doses of YL202 will be infused IV into each patient for 60 ±10 minutes.

Locations

Country Name City State
China Jilin Provincial Cancer Hospital Changchun Jilin
China Hunan Cancer Hospital Changsha Hunan
China Fujian Cancer Hospital Fuzhou Fujian
China The First Affiliated Hospital of Zhejiang University School of Medicine Hangzhou Zhejiang
China Zhejiang Cancer Hospital Hangzhou Zhejiang
China Taizhou Hospital of Zhejiang Province Taizhou Zhejiang
United States Karmanos Cancer Institute Detroit Michigan
United States The University of Texas MD Anderson Cancer Center Houston Texas
United States BRCR Global Plantation Florida
United States Summit Cancer Center Spokane Valley Washington
United States UT health east Texas HOPE Cancer Center Tyler Texas

Sponsors (1)

Lead Sponsor Collaborator
MediLink Therapeutics (Suzhou) Co., Ltd.

Countries where clinical trial is conducted

United States,  China, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluate the duration of response (DoR) DoR: defined as the time interval from the date of the first documentation of objective response (CR or PR) to the date of the first documentation of PD. The DoR will be assessed for patients with a response (CR or PR) only. Approximately within 36 months
Other Evaluate the time to response (TTR) TTR: defined as the time interval from the date of the first dose of study drug to the date of the first documentation of objective response (CR or PR). Approximately within 36 months
Other Evaluate the progression-free survival (PFS) PFS: defined as the time interval from the date of the first dose of study drug to the date of first documentation of PD or death due to any cause, whichever occurs first. Approximately within 36 months
Other Evaluate the overall survival (OS) OS: defined as the time interval from the date of the first dose of study drug to the date of death due to any cause. Approximately within 36 months
Primary Evaluate the occurrence of DLTs during the first cycle At the end of Cycle 1 (each cycle is 21 days)
Primary Evaluate the AEs as characterized by type, frequency, severity, timing, seriousness and relationship to study treatment By the global end of trial date, approximately within 36 months
Secondary Characterize the PK parameter AUC Approximately within 36 months
Secondary Characterize the PK parameter Cmax Approximately within 36 months
Secondary Characterize the PK parameter Ctrough Approximately within 36 months
Secondary Characterize the PK parameter CL Approximately within 36 months
Secondary Characterize the PK parameter Vd Approximately within 36 months
Secondary Characterize the PK parameter t1/2 Approximately within 36 months
Secondary Assess the incidence of anti-YL202 antibodies Approximately within 36 months
Secondary Evaluate the objective response rate (ORR) ORR: defined as the proportion of patients who achieved a best overall response of complete response (CR) or partial response (PR). Approximately within 36 months
Secondary Evaluate the disease control rate (DCR) DCR: defined as the proportion of patients who achieved a best overall response of CR, PR or stable disease (SD). Approximately within 36 months
Secondary Evaluate the best tumor response Best tumor response: defined as the maximum percentage change in the sum of longest dimensions of measurable lesion(s) at any time during the study. Approximately within 36 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Withdrawn NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Completed NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A